1. CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent.
- Author
-
Kinney BLC, Brammer B, Kansal V, Parrish CJ, Kissick HT, Liu Y, Saba NF, Buchwald ZS, El-Deiry MW, Patel MR, Boyce BJ, Kaka AS, Gross JH, Baddour HM, Chen AY, and Schmitt NC
- Subjects
- Humans, Male, Middle Aged, Female, Aged, Interferon-gamma metabolism, Adult, Cell Proliferation, Aged, 80 and over, CD28 Antigens metabolism, CD57 Antigens metabolism, Head and Neck Neoplasms immunology, Head and Neck Neoplasms pathology, Head and Neck Neoplasms metabolism, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, Cellular Senescence immunology
- Abstract
T lymphocytes expressing CD57 and lacking costimulatory receptors CD27/CD28 have been reported to accumulate with aging, chronic infection, and cancer. These cells are described as senescent, with inability to proliferate but enhanced cytolytic and cytokine-producing capacity. However, robust functional studies on these cells taken directly from cancer patients are lacking. We isolated these T cells and their CD27/28+ counterparts from blood and tumor samples of 50 patients with previously untreated head and neck cancer. Functional studies confirmed that these cells have enhanced ability to degranulate and produce IFN-γ. They also retain the ability to proliferate, thus are not senescent. These data suggest that CD27/28-CD57+ CD8+ T cells are a subset of highly differentiated, CD45RA+ effector memory (T
EMRA ) cells with retained proliferative capacity. Patients with > 34% of these cells among CD8+ T cells in the blood had a higher rate of locoregional disease relapse, suggesting these cells may have prognostic significance., Competing Interests: NCS discloses consulting fees from Sensorion, Regeneron, and GeoVax in addition to research funding from Astex Pharmaceuticals. The authors have no conflicting financial interests related to this work., (© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.)- Published
- 2024
- Full Text
- View/download PDF